Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer's disease from controls.
Eur Arch Psychiatry Clin NeurosciAug 17, 2026 (epub)
Sophia Rutt, Paulina Tegethoff, Marleen Taute et al.
✦ AI-curated · Sources linked
In 30 seconds
This clinical trial evaluated the diagnostic accuracy of BraincheX, a self-administered digital cognitive test, in distinguishing early Alzheimer's disease (AD) from cognitively healthy controls. The study involved 56 participants and found that BraincheX achieved an area under the curve (AUC) of 0.86, with a sensitivity of 89.7% and specificity of 68.0%, indicating strong diagnostic potential.
Key findings
- BraincheX total score achieved an AUC of 0.86 for differentiating early AD from controls.
- Sensitivity of BraincheX was 89.7%, while specificity was 68.0%.
- Significant group differences were confirmed across all BraincheX subtests (p < .01).
- BraincheX total scores correlated strongly with CERAD total scores (r = .73, p < .001).
Why it matters
The study highlights the potential of digital cognitive assessments to improve accessibility and efficiency in diagnosing early Alzheimer's disease, which may enhance early intervention strategies.